These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
129 related articles for article (PubMed ID: 21351459)
1. [The crystalline polymorph control and selection of gabapentin with polymer heteronuclei]. Yang L; Ru ML; Lang MD Yao Xue Xue Bao; 2010 Jan; 45(1):109-13. PubMed ID: 21351459 [TBL] [Abstract][Full Text] [Related]
2. Progressive steps of polymorphic transformation of gabapentin polymorphs studied by hot-stage FTIR microspectroscopy. Hsu CH; Ke WT; Lin SY J Pharm Pharm Sci; 2010; 13(1):67-77. PubMed ID: 20456832 [TBL] [Abstract][Full Text] [Related]
3. Quantification of gabapentin polymorphs in gabapentin/excipient mixtures using solid state Tinmanee R; Larsen SC; Morris KR; Kirsch LE J Pharm Biomed Anal; 2017 Nov; 146():29-36. PubMed ID: 28843174 [TBL] [Abstract][Full Text] [Related]
4. Crystal structures of a new polymorphic form of gabapentin monohydrate and the e and z isomers of 4-tertiarybutylgabapentin. Vasudev PG; Aravinda S; Ananda K; Veena SD; Nagarajan K; Shamala N; Balaram P Chem Biol Drug Des; 2009 Jan; 73(1):83-96. PubMed ID: 19016796 [TBL] [Abstract][Full Text] [Related]
6. Solid-state transformation of different gabapentin polymorphs upon milling and co-milling. Lin SY; Hsu CH; Ke WT Int J Pharm; 2010 Aug; 396(1-2):83-90. PubMed ID: 20561572 [TBL] [Abstract][Full Text] [Related]
7. The stabilizing effect of moisture on the solid-state degradation of gabapentin. Zong Z; Desai SD; Kaushal AM; Barich DH; Huang HS; Munson EJ; Suryanarayanan R; Kirsch LE AAPS PharmSciTech; 2011 Sep; 12(3):924-31. PubMed ID: 21744168 [TBL] [Abstract][Full Text] [Related]
8. C9 helices and ribbons in gamma-peptides: crystal structures of gabapentin oligomers. Vasudev PG; Shamala N; Ananda K; Balaram P Angew Chem Int Ed Engl; 2005 Aug; 44(31):4972-5. PubMed ID: 16003813 [No Abstract] [Full Text] [Related]
9. Comparative effects of some hydrophilic excipients on the rate of gabapentin and baclofen lactamization in lyophilized formulations. Cutrignelli A; Denora N; Lopedota A; Trapani A; Laquintana V; Latrofa A; Trapani G; Liso G Int J Pharm; 2007 Mar; 332(1-2):98-106. PubMed ID: 17071027 [TBL] [Abstract][Full Text] [Related]
10. Polymorphism control of an active pharmaceutical ingredient beneath calixarene-based Langmuir monolayers. Tulli LG; Moridi N; Wang W; Helttunen K; Neuburger M; Vaknin D; Meier W; Shahgaldian P Chem Commun (Camb); 2014 Apr; 50(30):3938-40. PubMed ID: 24599407 [TBL] [Abstract][Full Text] [Related]
12. Stability of gabapentin in extemporaneously compounded oral suspensions. Friciu M; Roullin VG; Leclair G PLoS One; 2017; 12(4):e0175208. PubMed ID: 28414771 [TBL] [Abstract][Full Text] [Related]
13. Molecular structure, electronic properties, NLO, NBO analysis and spectroscopic characterization of Gabapentin with experimental (FT-IR and FT-Raman) techniques and quantum chemical calculations. Sinha L; Karabacak M; Narayan V; Cinar M; Prasad O Spectrochim Acta A Mol Biomol Spectrosc; 2013 May; 109():298-307. PubMed ID: 23545435 [TBL] [Abstract][Full Text] [Related]
14. Nanosponge-based pediatric-controlled release dry suspension of Gabapentin for reconstitution. Rao MR; Bhingole RC Drug Dev Ind Pharm; 2015; 41(12):2029-36. PubMed ID: 26006328 [TBL] [Abstract][Full Text] [Related]